Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions.

By A. Vermes, H. Guchelaar, J. Dankert. Journal of Antimicrobial Chemotherapy, 2000

740 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. (2012, background): “Furthermore, due to the multiple steps in its mode of action, including transport into the cell and deamination of the active compound, flucytosine is normally used only in combination with other agents, including amphotericin B and fluconazole (Vermes et al., 2000).”
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “Peak concentrations <100 mg/L are recommended to avoid the predictable liver and bone marrow effects [119].”
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007, background): “Despite a general consensus regarding the clinical efficacy of 5FC when used in combination with other agents (68), clinicians are often hesitant to use this antifungal agent due to concerns about toxicity (78, 297) and either primary or secondary resistance (155, 280, 281, 297).”